Verve Therapeutics, Inc.
NASDAQ:VERV
5.64 (USD) • At close December 31, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
2023 | 2022 | 2021 | 2020 | 2019 | |
---|---|---|---|---|---|
Operating Activities: | |||||
Net Income
| -200.068 | -157.387 | -120.314 | -45.704 | -19.297 |
Depreciation & Amortization
| 5.455 | 2.804 | 1.535 | 1.328 | 0.106 |
Deferred Income Tax
| 0 | 0 | 1.508 | 0.38 | -0.072 |
Stock Based Compensation
| 35.116 | 22.477 | 7.072 | 0.85 | 0.446 |
Change In Working Capital
| 17.703 | 8.38 | -2.912 | 2.642 | 2.661 |
Accounts Receivables
| 0 | -1.012 | 0 | 0 | 0 |
Inventory
| 0 | 1.012 | 0 | 0 | 0 |
Accounts Payables
| 3.91 | -5.216 | 6.829 | -1.898 | 1.735 |
Other Working Capital
| 13.793 | 13.596 | -9.741 | 4.54 | 0.926 |
Other Non Cash Items
| -7.755 | 1.394 | 35.231 | 5.239 | 8.714 |
Operating Cash Flow
| -149.549 | -122.332 | -77.88 | -35.265 | -7.442 |
Investing Activities: | |||||
Investments In Property Plant And Equipment
| -9.283 | -13.232 | -4.359 | -3.424 | -1.857 |
Acquisitions Net
| 0 | 142.723 | 234.739 | 47.703 | 10.901 |
Purchases Of Investments
| -517.14 | -479.401 | -371.494 | -98.484 | -22.001 |
Sales Maturities Of Investments
| 554.113 | 336.678 | 136.755 | 50.781 | 11.1 |
Other Investing Activites
| 0 | -142.723 | -234.739 | -47.703 | -10.901 |
Investing Cash Flow
| 27.69 | -155.955 | -239.098 | -51.127 | -12.758 |
Financing Activities: | |||||
Debt Repayment
| 0 | 0 | 0 | 0 | 0 |
Common Stock Issued
| 210.456 | 326.495 | 285.214 | 92.627 | 18.04 |
Common Stock Repurchased
| 0 | 0 | 0 | 0 | 0 |
Dividends Paid
| 0 | 0 | 0 | 0 | 0 |
Other Financing Activities
| 2.121 | 2.461 | 91.875 | 92.627 | 17.954 |
Financing Cash Flow
| 212.577 | 328.956 | 377.089 | 92.627 | 17.954 |
Other Information: | |||||
Effect Of Forex Changes On Cash
| 0 | 0 | 0 | 0 | 0 |
Net Change In Cash
| 90.718 | 50.669 | 60.111 | 6.235 | -2.246 |
Cash At End Of Period
| 210.954 | 120.236 | 69.567 | 9.456 | 3.221 |